Premium
Drug‐eluting stent task force: Final report and recommendations of the working committees on cost‐effectiveness/economics, access to care, and medicolegal issues
Author(s) -
Hodgson John McB.,
Bottner Randy K.,
Klein Lloyd W.,
Walpole Howard T.,
Cohen David J.,
Cutlip Donald E.,
Fenninger Randolph B.,
Firth Brian G.,
Greenberg Dan,
Kalisky Ilona,
Meskan Thomas,
Powell Wayne,
Stone Gregg W.,
Zito James P.,
Clark Mary Ann
Publication year - 2004
Publication title -
catheterization and cardiovascular interventions
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.988
H-Index - 116
eISSN - 1522-726X
pISSN - 1522-1946
DOI - 10.1002/ccd.20025
Subject(s) - medicine , reimbursement , restenosis , task force , stent , psychological intervention , coronary artery disease , percutaneous coronary intervention , angioplasty , intensive care medicine , health care , cardiology , nursing , myocardial infarction , public administration , political science , economics , economic growth
Abstract Coronary artery disease remains a major health problem worldwide. Since introduction of percutaneous transluminal coronary angioplasty and stents, much progress has been made. Percutaneous coronary intervention, however, has been limited by restenosis (repeat obstruction of arteries that have been previously treated. Introduction of drug‐eluting stents (DESs) in April 2003 was a major breakthrough in preventing restenosis. In March 2003, The Society for Cardiovascular Angiography and Interventions (SCAI) published a position statement on the clinical implications of DESs, recommending an evidence‐based adoption strategy. Subsequently, in May 2003, SCAI formed a multidisciplinary Drug Eluting Stent (DES) Task Force to address the significant nonclinical ramifications posed by DESs: medicolegal, financial, and access to care. The Task Force included representatives from physician societies, industry, academia, the reimbursement community, and health policy organizations. The resultant report presents analyses, options, and recommendations regarding those nonclinical issues based on the collective experience and knowledge of the Task Force members. The Task Force trusts that this report will be of value to the diverse constituencies involved with introduction of this important new technology. Catheter Cardiovasc Interv 2004;62: 1–17. © 2004 Wiley‐Liss, Inc.